Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Investors Liked AbbVie's Q4 Results

By Keith Speights - Feb 3, 2021 at 12:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Better-than-expected top and bottom lines plus positive guidance were exactly what Wall Street wanted.

Shares of AbbVie (ABBV 1.08%) soared 21% in 2020, the stock's best performance since 2017. The big pharma hasn't gotten off to a great start so far in 2021, though, with shares down year to date. 

The beginning of a bounce could be underway now, however, for the Dividend Aristocrat. AbbVie announced positive fourth-quarter results before the market opened on Wednesday. Here are the highlights from the company's update.

Female scientist holding pill in gloved hand.

Image Source: Getty Images.

By the numbers

AbbVie announced revenue of $13.9 billion in the fourth quarter, a 59% year-over-year jump. This result also topped the average analyst revenue estimate of $13.7 billion.

The company reported net income in the fourth quarter of $36 million, or $0.01 per share, based on generally accepted accounting principles (GAAP). This was a steep decline from AbbVie's GAAP earnings of $2.8 billion, or $1.88 per share, in the prior-year period.

But it was a different story with AbbVie's adjusted bottom line. The drugmaker posted adjusted earnings of $2.92 share, up from $2.21 per share in the same period in 2019. This result easily beat the Wall Street consensus for adjusted earnings of $2.85.

Behind the numbers

Humira remained AbbVie's top-selling product in the fourth quarter. Total sales for the autoimmune-disease drug rose 4.8% year over year to $5.1 billion. Although international sales for Humira fell 9.4%, the decline was more than offset by 8.2% growth in the U.S., which is a bigger market for the drug.

AbbVie's successors to Humira turned in strong performances in the fourth quarter. Sales for Rinvoq and Skyrizi totaled $281 million and $525 million, respectively. Both autoimmune-disease drugs won their first regulatory approvals in 2019.

Momentum for the company's blood cancer franchise also carried over into the fourth quarter. Sales for Imbruvica jumped 9.8% year over year to $1.4 billion. Sales for Venclexta skyrocketed 46.2% to $365 million. 

Some products picked up by AbbVie with its acquisition of Allergan also contributed to overall growth. Botox cosmetic sales rose more than 9% year over year to $493 million. Sales for antipsychotic drug Vraylar soared 38% to $401 million.

Looking ahead

AbbVie anticipates GAAP earnings per share for the full-year 2021 between $6.69 and $6.89. It expects adjusted EPS between $12.32 and $12.52. This forecast reflects solid growth compared to 2020.

The company also provided longer-term sales guidance. It looks for strong overall sales growth through 2023, when Humira loses exclusivity in the U.S. It anticipates that total sales will decline in 2023, followed by modest overall revenue growth in 2025. For the rest of the decade, though, the drugmaker projects a high-single-digit compound annual growth rate. 

This outlook should be encouraging for investors, especially those who count on AbbVie's dividend. That juicy payout looks safe for a long time to come.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
$154.14 (1.08%) $1.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.